What is it about?
The rate of incidence of SIOL was 28% in our patients with IOL, which shows it is not a rare type of IOL. SIOL was classified into three subtypes based on its development. Clinical outcomes of SIOL patients revealed poor prognosis and common relapse, as several types, including eye lesions, CNSL and systemic lesions, occurred at high frequency within a short period.
Featured Image
Why is it important?
SIOL is not a rare type of IOL as the rate of incidence of SIOL was 28% in our IOL patients. Even with various preventive chemo-radiotherapies, SIOL tended to recur repeatedly at high frequencies within short periods from the diagnosis and clinical outcomes were poor
Perspectives
Even though treatments for PIOL have improved as the result of several clinical trials, an effective treatment for SIOL remains to be determined.
Kazuki Taoka
Tokyo University
Read the Original
This page is a summary of: Clinical features and outcomes of secondary intraocular lymphoma, British Journal of Haematology, November 2017, Wiley,
DOI: 10.1111/bjh.15005.
You can read the full text:
Resources
New treatment suppresses relapse of eye lymphoma in brain
A University of Tokyo research group has found that a new treatment regimen is effective in curtailing the high rate of an intractable eye disease, intraocular lymphoma, from spreading to the brain. This new therapy promises to greatly improve the prognosis of the disease and is expected to become a new treatment protocol in the future.
New treatment suppresses relapse of eye lymphoma in brain
A University of Tokyo research group has found that a new treatment regimen is effective in curtailing the high rate of an intractable eye disease, intraocular lymphoma, from spreading to the brain. This new therapy promises to greatly improve the prognosis of the disease and is expected to become a new treatment protocol in the future.
Contributors
The following have contributed to this page
